
MaMome provides early, personalized pregnancy risk screening to protect the short- and long-term health of mothers and babies. It analyzes maternal microbiome samples and applies machine learning models to detect biological signals that indicate elevated risk of pregnancy complications. MaMome operates as a healthcare-focused platform (B2B) that integrates microbiome-based testing, AI-driven risk models, and HIPAA-compliant data handling for clinicians, health systems, and researchers. The company also supports AI-guided personalized nutrition and probiotic recommendations as part of care pathways. MaMome targets integration into routine maternal care to enable earlier intervention and monitoring across clinical and research settings.

MaMome provides early, personalized pregnancy risk screening to protect the short- and long-term health of mothers and babies. It analyzes maternal microbiome samples and applies machine learning models to detect biological signals that indicate elevated risk of pregnancy complications. MaMome operates as a healthcare-focused platform (B2B) that integrates microbiome-based testing, AI-driven risk models, and HIPAA-compliant data handling for clinicians, health systems, and researchers. The company also supports AI-guided personalized nutrition and probiotic recommendations as part of care pathways. MaMome targets integration into routine maternal care to enable earlier intervention and monitoring across clinical and research settings.
Focus: Microbiome analysis + ML for early pregnancy risk screening
Founded: May 2022
Headquarters: Brooklyn, New York, United States
Last funding: Grant from NIH announced Jul 22, 2024
Status (as listed): Closed (per profile listing)
Maternal health — early detection and monitoring of pregnancy complications via biological signals in the maternal microbiome.
2022
Biotechnology
300000
Grant announced Jul 22, 2024
“National Institutes of Health”